Jama Neurology

JAMA Neurology (jama-neurology)

Journal positioning

JAMA Neurology is a JAMA Network specialty journal for clinical neurology research across the breadth of neurological disease — neurodegenerative, cerebrovascular, neuroimmune, epilepsy, movement, neuromuscular, and headache disorders. It favors randomized clinical trials and rigorous observational and biomarker studies tied to clinically meaningful neurological outcomes, with JAMA's emphasis on adequate power, validated endpoints, and direct relevance to neurological practice. Mechanistic bench neuroscience, small case series, and biomarker correlations without clinical endpoints are a weak fit; that work belongs to a translational-neuroscience venue. This skill is a fit / venue-selection / re-framing aid; it is not clinical or regulatory advice and does not replace the journal's current instructions for authors. Before submitting, re-check the live JAMA Neurology author instructions.

When to trigger

• The author names JAMA Neurology for a clinical-neurology trial, cohort, or biomarker study and wants a fit/framing check.
• A neurological study must be re-framed around a validated clinical or functional endpoint (disability scale, cognitive measure, seizure freedom) for a practicing- neurology audience.
• The author is choosing between JAMA Neurology, JAMA, a mechanistic-translational venue (brain), or a cerebrovascular-specific venue (stroke).
• The author needs the journal's reporting-guideline, registration, and desk-reject expectations for neurology work.

Scope & topic fit

• Randomized clinical trials in neurology (disease-modifying, symptomatic, or device/neuromodulation), including pragmatic designs.
• Observational and cohort studies across neurodegenerative (Alzheimer, Parkinson), cerebrovascular, demyelinating, epilepsy, and neuromuscular disease with clinical endpoints.
• Fluid and imaging biomarker studies (e.g., amyloid/tau, neurofilament, MRI markers) validated against diagnosis, progression, or outcome.
• Diagnostic, prognostic, and natural-history studies with validated neurological scales and meaningful follow-up.
• Health-services, epidemiology, and disparities research in neurological disease.
• Systematic reviews and meta-analyses answering a focused neurological question.

Method & evidence bar

• Trials must be adequately powered with a prespecified, clinically meaningful primary endpoint using validated neurological/functional outcome measures; biomarker-only endpoints need strong justification.
• The applicable reporting guideline and checklist are required: CONSORT for trials, STROBE for observational studies, PRISMA for systematic reviews; biomarker/diagnostic work should follow STARD-style rigor where relevant.
• Trials require prospective registration; registration number, protocol, and statistical-analysis plan are expected.
• Outcome scales must be validated and analyzed appropriately (e.g., ordinal/repeated- measures methods); minimal clinically important differences should be addressed.
• Observational and biomarker claims must address confounding, verification bias, and the diagnosis reference standard; causal language must match the design.
• Longitudinal/progression studies need adequate follow-up and handling of dropout and competing risks.

Structure & house style

• JAMA Network format with a structured abstract and a Key Points box; re-check current article types (Original Investigation, Brief Report, Research Letter, etc.) and limits on the live guide.
• The introduction frames a focused, practice-relevant neurological question; the discussion states the clinical or diagnostic implication plainly.
• Tables/figures follow JAMA Network statistical-reporting standards; CONSORT/STROBE flow diagrams and outcome-distribution figures are expected where applicable.
• Supplements carry the protocol, SAP, scale definitions, and additional analyses.